FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2811175890> ?p ?o ?g. }

• W2811175890 abstract "ABSTRACT Introduction Morgana is a ubiquitously expressed protein with chaperone activity per se and HSP90 co-chaperone function. High Morgana expression correlates with high tumour grade, mitosis number, and lymph node positivity in different breast cancer subtypes. Several chaperones are overexpressed in a wide range of human cancers and are implicated in tumour progression. Moreover, it has become evident that also from the extracellular compartment, where surprisingly chaperones and co-chaperones are actively released by cancer and immune cells, they favour tumour progression. If, the cytoplasmic role of Morgana has been well characterised in tumorigenesis and metastasis formation of Triple-Negative Breast Cancer (TNBC), nothing is known about extracellular Morgana (eMorgana). Material and methods Conditioned medium from human and murine TNBCs cell lines were analysed for Morgana presence. To address the role of eMorgana, a Maltose Binding Protein (MBP) fused recombinant protein was produced in ClearColi BL21 and used to evaluate eMorgana role in migration, treating MDA-231 and BT-549. The identification of Morgana receptor was performed indirectly, through the inhibition of Toll-like 2 and Toll-like 4 receptors (TLR2, TLR4). The activity of extracellular Morgana was inhibited, in mice injected with the syngenic cancer cell line E0771, using the homemade blocking antibody 5B11. Results and discussions Morgana is secreted by TNBC cell lines and as for other chaperones and co-chaperones, Morgana reaches the outside with an unconventional mechanism. From the extracellular compartment Morgana is able to induce cell migration, through theTLR2 and TLR4. Blocking of eMorgana with 5B11 inhibits migration in vitro and proliferation in vivo. Different efforts are needed to understand if Morgana binds to TLRs alone or through HSP90 and the consequently downstream signalling pathway. Moreover since TLR are prevalently expressed by immune cells it is important to address the role of eMorgana in this context and the possible crosstalk between the tumour and microenvironment. Conclusion Since TNBCs have an high rate of recurrence and poor prognosis, the identification of innovative treatments is an urgent need. In this view, although many other studies are required, eMorgana in serum patients could represent a new biomarker and its targeting a possible clinical approach in breast cancers." @default.
• W2811175890 created "2018-07-10" @default.
• W2811175890 creator A5004265854 @default.
• W2811175890 creator A5046747249 @default.
• W2811175890 creator A5054519058 @default.
• W2811175890 creator A5057698241 @default.
• W2811175890 creator A5075548163 @default.
• W2811175890 creator A5075961136 @default.
• W2811175890 creator A5083383348 @default.
• W2811175890 date "2018-06-01" @default.
• W2811175890 modified "2023-09-23" @default.
• W2811175890 title "PO-237 Neutralising extracellular morgana impairs breast tumour growth and migration" @default.
• W2811175890 doi "https://doi.org/10.1136/esmoopen-2018-eacr25.753" @default.
• W2811175890 hasPublicationYear "2018" @default.
• W2811175890 type Work @default.
• W2811175890 sameAs 2811175890 @default.
• W2811175890 citedByCount "0" @default.
• W2811175890 crossrefType "journal-article" @default.
• W2811175890 hasAuthorship W2811175890A5004265854 @default.
• W2811175890 hasAuthorship W2811175890A5046747249 @default.
• W2811175890 hasAuthorship W2811175890A5054519058 @default.
• W2811175890 hasAuthorship W2811175890A5057698241 @default.
• W2811175890 hasAuthorship W2811175890A5075548163 @default.
• W2811175890 hasAuthorship W2811175890A5075961136 @default.
• W2811175890 hasAuthorship W2811175890A5083383348 @default.
• W2811175890 hasBestOaLocation W28111758901 @default.
• W2811175890 hasConcept C28406088 @default.
• W2811175890 hasConcept C502942594 @default.
• W2811175890 hasConcept C71924100 @default.
• W2811175890 hasConcept C86803240 @default.
• W2811175890 hasConcept C95444343 @default.
• W2811175890 hasConceptScore W2811175890C28406088 @default.
• W2811175890 hasConceptScore W2811175890C502942594 @default.
• W2811175890 hasConceptScore W2811175890C71924100 @default.
• W2811175890 hasConceptScore W2811175890C86803240 @default.
• W2811175890 hasConceptScore W2811175890C95444343 @default.
• W2811175890 hasLocation W28111758901 @default.
• W2811175890 hasLocation W28111758902 @default.
• W2811175890 hasOpenAccess W2811175890 @default.
• W2811175890 hasPrimaryLocation W28111758901 @default.
• W2811175890 hasRelatedWork W1511185158 @default.
• W2811175890 hasRelatedWork W1548285582 @default.
• W2811175890 hasRelatedWork W164794239 @default.
• W2811175890 hasRelatedWork W1868824221 @default.
• W2811175890 hasRelatedWork W2016451291 @default.
• W2811175890 hasRelatedWork W2051616588 @default.
• W2811175890 hasRelatedWork W2170075711 @default.
• W2811175890 hasRelatedWork W2214816483 @default.
• W2811175890 hasRelatedWork W2333971940 @default.
• W2811175890 hasRelatedWork W2460577046 @default.
• W2811175890 hasRelatedWork W2499103983 @default.
• W2811175890 hasRelatedWork W2566642161 @default.
• W2811175890 hasRelatedWork W2903601532 @default.
• W2811175890 hasRelatedWork W2914502901 @default.
• W2811175890 hasRelatedWork W2945412645 @default.
• W2811175890 hasRelatedWork W2957946774 @default.
• W2811175890 hasRelatedWork W2981934598 @default.
• W2811175890 hasRelatedWork W3002765893 @default.
• W2811175890 hasRelatedWork W3201805245 @default.
• W2811175890 hasRelatedWork W3206470531 @default.
• W2811175890 isParatext "false" @default.
• W2811175890 isRetracted "false" @default.
• W2811175890 magId "2811175890" @default.
• W2811175890 workType "article" @default.